Thirteen chronic myeloid leukemia (CML) patients, 10 with variant Philadelphia (Ph) translocations and 3 Ph negative cases, were analyzed by fluorescence in situ hybridization (FISH) with the use of BCR and ABL cosmid probes and a chromosome 22 painting probe. In the variant Ph translocations, the BCR-ABL fusion gene was located on the Ph chromosome; in 1 CML Ph-negative patient, the BCR-ABL fusion gene was located on the Ph chromosome; and, in 2 patients, it was located on chromosome 9. The chromosome 22 painting probe was detected on the third-party chromosome of the variant translocation, and in none of the variant translocations was there any detectable signal on chromosome 9. In CML patients with clonal evolution of a simple Ph, a signal of the chromosome 22 painting probe was detected on the der(9) of the Ph translocation. It was concluded that the variant Ph translocations evolved simultaneously in a three-way rearrangement. The clinical parameters of the 13 patients were similar to those of a large group of CML patients with a simple Ph translocation. It is suggested that, to determine the prognosis of CML patients with a complex karyotype, FISH analysis with a chromosome 22 painting probe be performed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0165-4608(99)00067-9 | DOI Listing |
Farm Hosp
January 2025
Servicio de Farmacia, Complejo Hospitalario Universitario de Canarias, Santa Cruz de Tenerife, España; Unidad de Investigación, Complejo Hospitalario Universitario de Canarias, Santa Cruz de Tenerife, España. Electronic address:
Aims: Tyrosine kinase inhibitors (TKIs) have been successful in changing the course of chronic myeloid leukaemia (CML) due to their high efficacy. However, their effectiveness is conditioned by adherence to treatment. The aim of this study was to analyse the adherence of CML patients treated with TKIs and to evaluate the impact of pharmaceutical care on adherence in a prospective and interventional manner.
View Article and Find Full Text PDFArch Pathol Lab Med
January 2025
the Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis (Stohler, Vance).
Context.—: Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by proliferation of the granulocytic cell line. The incidence of CML in Kenya is estimated at near 2000 cases annually.
View Article and Find Full Text PDFCureus
December 2024
Department of Pediatrics, University of Yamanashi, Chuo, JPN.
The T315I-inclusive compound mutation, the multiple mutations including the T315I mutation on the same BCR::ABL1 gene, confers resistance to diverse tyrosine kinase inhibitors (TKIs). Development of the F311I/T315I compound mutation has been reported in chronic myeloid leukemia patients who sequentially showed clinical resistance to imatinib and dasatinib. The establishment of a human leukemia model with the T315I-inclusive compound mutation remains an experimental challenge.
View Article and Find Full Text PDFJ Community Hosp Intern Med Perspect
January 2025
Department of Internal Medicine, Temple University Health System, Philadelphia, PA, USA.
Background: Spontaneous splenic rupture (SSR) is a known complication of hematologic malignancy. Rare cases have been reported in which patients presented with SSR prior to diagnosis of chronic myeloid leukemia (CML). We present a case of atraumatic SSR due to CML presenting as persistent abdominal pain.
View Article and Find Full Text PDFJ Trauma Acute Care Surg
January 2025
From the Department of Surgery (A.M.C., L.V., A.L.C.), University of Pittsburgh; University of Pittsburgh School of Public Health (J.F.L., S.R.W.); Department of Emergency Medicine (F.X.G.), University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Surgery (B.A.C.), University of Texas Health Science Center, Houston, Texas; Department of Surgery (J.W.C.), University of Pennsylvania, Philadelphia, Pennsylvania; Department of Surgery (M.A.S.), Oregon Health & Science University, Portland, Oregon; Department of Surgery (E.E.M.), Ernest E. Moore Shock Trauma Center at Denver Health, University of Colorado Health Sciences Center, Denver, Colorado; Department of Surgery (N.N.), University of Miami/Jackson Memorial Hospital, Miami, Florida; Department of Surgery (J.P.M.), University of Texas Southwestern Medical Center, Dallas, Texas; and Department of Pathology (M.H.Y.), Department of Radiology (V.A.), and Trauma and Transfusion Medicine Research Center, Department of Surgery (J.B.B., C.M.L., M.D.N., R.M.F., J.L.S.), University of Pittsburgh, Pittsburgh, Pennsylvania.
Introduction: Whole blood resuscitation is associated with survival benefits in observational cohort studies. The mechanisms responsible for outcome benefits have not been adequately determined. We sought to characterize the achievement of hemostasis across patients receiving early whole blood versus component resuscitation.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!